The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies
Authors' conclusion
Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.
Study context
- Population
- Patients with juvenile idiopathic inflammatory myopathies (JIIM), current age <21 years; survey via CureJM, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board54 completed full survey
- Participants
- 70 patients
- Outcome
- Impact of COVID-19 pandemic on JIIM
Methodological detailspatient/caregiver survey, Research Electronic Data Capture (REDCap)
- Patient/caregiver survey
- REDCap
Main finding
As reported in the abstract
- Tested positive for COVID-19
- 27 out of 57 (47%)
- Tested positive more than once
- 7 (12%)
- Mild COVID-19 symptoms among positive
- 24 out of 27 (89%)
- Hospitalisation for COVID-19
- 0
- JIIM flare after COVID-19
- 4
- Vaccinated against COVID-19
- 37 out of 54 (69%)
- Psychosocial concerns related to pandemic
- 21 out of 54 (39%)
Observational data: associations, not effects.
Safety
Minor COVID-19 vaccine side effects
- Minor vaccine side effects
- 9 out of 37 (24%)
- JIIM flare post vaccination
- 1
Original publication
The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies. Pediatr Rheumatol Online J. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →